Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Increase in Short Interest

Posted by Donald Scott on Jul 30th, 2024

Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 144,900 shares, a growth of 23.1% from the June 30th total of 117,700 shares. Based on an average trading volume of 277,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.7% of the company’s shares are short sold.

Xilio Therapeutics Stock Down 3.0 %

Shares of NASDAQ:XLO opened at $0.98 on Tuesday. The firm has a market cap of $36.17 million, a price-to-earnings ratio of -0.38 and a beta of -0.09. Xilio Therapeutics has a 12 month low of $0.49 and a 12 month high of $2.94. The company’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $0.92.

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.29). Research analysts expect that Xilio Therapeutics will post -1.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC acquired a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO – Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics as of its most recent SEC filing. 54.29% of the stock is currently owned by institutional investors.

About Xilio Therapeutics

(Get Free Report)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.